Bridgewater Associates LP Sells 19,677 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bridgewater Associates LP trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 60.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,749 shares of the company's stock after selling 19,677 shares during the quarter. Bridgewater Associates LP's holdings in IDEXX Laboratories were worth $6,441,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of IDXX. Freedom Investment Management Inc. boosted its position in shares of IDEXX Laboratories by 5.6% in the 3rd quarter. Freedom Investment Management Inc. now owns 1,539 shares of the company's stock worth $778,000 after purchasing an additional 81 shares during the last quarter. Townsquare Capital LLC lifted its stake in IDEXX Laboratories by 23.7% in the third quarter. Townsquare Capital LLC now owns 5,058 shares of the company's stock valued at $2,555,000 after buying an additional 970 shares during the period. J. Stern & Co. LLP lifted its stake in IDEXX Laboratories by 48.0% in the third quarter. J. Stern & Co. LLP now owns 3,320 shares of the company's stock valued at $1,677,000 after buying an additional 1,077 shares during the period. Avestar Capital LLC grew its position in shares of IDEXX Laboratories by 8.6% during the 3rd quarter. Avestar Capital LLC now owns 759 shares of the company's stock worth $383,000 after buying an additional 60 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $341,000. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Down 0.0 %

Shares of IDEXX Laboratories stock traded down $0.01 during trading on Friday, reaching $421.75. The stock had a trading volume of 338,607 shares, compared to its average volume of 505,750. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $34.53 billion, a price-to-earnings ratio of 40.67, a P/E/G ratio of 3.68 and a beta of 1.36. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The stock has a fifty day moving average price of $451.91 and a two-hundred day moving average price of $477.81.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm's revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.53 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company's stock, valued at $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 2.11% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Barclays reduced their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. JPMorgan Chase & Co. reduced their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research report on Thursday, October 10th. Piper Sandler reiterated a "neutral" rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $552.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.